Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder

The FDA approved Teva‘s vilazodone hydrochloride tablets in 10 mg, 20 mg and 40 mg for treatment of major depressive disorder (MDD).

The Teva product is a generic of Allergan’s Viibryd tablets, which the agency approved in 2011 for treating MDD in adults. 

The approval marks the agency’s 82nd first-time generic approval in 2019 and the first generic approved for MDD.